
    
      This is a multicenter, open-label, single arm study designed to demonstrate durability of the
      treatment effect and to evaluate the short-term and longer-term safety profile of the Alair
      System in the United States in the intended use population (patients 18 years and older with
      severe persistent asthma).
    
  